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Dopaminergic medication for motor symptoms in Parkinson’s disease (PD) recently has
been linked with impulse control disorders, including pathological gambling (PG), which
affects up to 8% of patients. PG often is considered a behavioral addiction associated
with disinhibition, risky decision-making, and altered striatal dopaminergic neurotransmis-
sion. Using [11C]raclopride with positron emission tomography, we assessed dopaminergic
neurotransmission during Iowa Gambling Task performance. Here we present data from a
single patient with PD and concomitant PG.We noted a marked decrease in [11C]raclopride
binding in the left ventral striatum upon gambling, indicating a gambling-induced dopamine
release. The results imply that PG in PD is associated with a high dose of dopaminergic
medication, pronounced motor symptomatology, young age at disease onset, high propen-
sity for sensation seeking, and risky decision-making. Overall, the findings are consistent
with the hypothesis of medication-related PG in PD and underscore the importance of
taking clinical variables, such as age and personality, into account when patients with PD
are medicated, to reduce the risk of PG.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder asso-
ciated with a progressive nigrostriatal and mesocorticolimbic
dopamine depletion, resulting in core motor symptoms of rest-
ing tremor, bradykinesia, rigidity, and postural instability. Recent
evidence established that dopaminergic medication administered
to relieve motor symptoms in PD may have detrimental effects
on cognitive functioning, including executive functions, decision-
making, and impulse control (Cools, 2006; Frank et al., 2007; Rowe
et al., 2008; Cools et al., 2009; Poletti et al., 2010). In early PD,
dopamine depletion is restricted to the dorsal striatum, leaving
the ventral striatum relatively intact. Thus, medication doses nec-
essary to remedy the dopaminergic loss in the dorsal striatum may
excessively stimulate the ventral striatum, potentially leading to
unusual repetitive and compulsive behaviors and impulse control
disorders, at least in a subgroup of PD patients (Cools, 2006; Rowe
et al., 2008; Cools et al., 2009; Poletti et al., 2010; Weintraub and
Nirenberg, 2012).
Pathological gambling (PG) is an impulse control disorder
characterized by recurrent maladaptive gambling behavior despite
personal, social, and financial consequences (APA, 1994), affecting
up to 8% of PD patients treated with dopamine agonists (Wein-
traub et al., 2010), a notably higher prevalence compared to a
prevalence of PG of 0.4–1.6% in the general population (Schreiber
et al., 2011). This particular complication to the treatment most
often occur subsequent to treatment initiation, or dosage increase,
and tend to improve or fully alleviate following reduction or dis-
continuation of the dopamine agonists (Callesen et al., 2013).
Besides dopamine agonists, additional risk factors include young
age at PD onset (often in early forties), male gender, personal
or family history of addictive behaviors, genetic factors, depres-
sive symptoms, and an impulsive and novelty seeking personality
(Voon et al., 2007, 2011a; Wu et al., 2009; Claassen et al., 2011;
Joutsa et al., 2012; Lee et al., 2012; Poletti and Bonuccelli, 2012;
Weintraub and Nirenberg, 2012; Callesen et al., 2013; Kim et al.,
2013). Often, PG is held to be a behavioral addiction associ-
ated with temporal discounting, disinhibition, and risky decision-
making, to which the Iowa Gambling Task (IGT) (Bechara et al.,
1994; Grant et al., 2000; Petry, 2001; Manes et al., 2002; Goudriaan
et al., 2005, 2006; Linnet et al., 2006, 2010, 2011a; Peterson et al.,
2010; van Holst et al., 2010) is applicable.
Commonly used as an experimental decision-making task, the
IGT mimics complex real-life decision-making processes embed-
ding factors of ambiguity, anticipation, reward, and punishment
(Bechara et al., 1994). Performance on the IGT is a sensitive mea-
sure of impaired decision-making in diverse neurological and
psychiatric conditions (Bechara et al., 1994). Patients with frontal
lesions,patients suffering from substance use disorders, and patho-
logical gamblers have demonstrated a preference for short-term
gains in spite of larger long-term losses when they perform the
IGT (Bechara et al., 1994; Grant et al., 2000; Petry, 2001; Manes
et al., 2002; Goudriaan et al., 2005, 2006; Linnet et al., 2006, 2010,
2011a; Peterson et al., 2010; van Holst et al., 2010). Furthermore,
Linnet et al. (2010, 2011a) recently showed that impaired IGT per-
formance in pathological gamblers is associated with an increased
dopamine release in the ventral striatum, which is crucial in
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reinforcement of behavior – including disadvantageous behavior
(Linnet et al., 2011b, 2012).
Likewise, studies of decision-making in PD with the IGT
reported poorer IGT performance in PD patients than in healthy
controls (Perretta et al., 2005; Mimura et al., 2006; Pagonabar-
raga et al., 2007; Kobayakawa et al., 2008; Ibarretxe-Bilbao
et al., 2009; Rossi et al., 2010; Poletti et al., 2011; Gescheidt
et al., 2012), also early in the disease (Perretta et al., 2005;
Ibarretxe-Bilbao et al., 2009). In contrast, Euteneuer et al.
(2009) showed intact IGT performance in PD patients, and
Gescheidt et al. (2012) demonstrated only slightly reduced
IGT performance in patients with early-onset PD compared to
healthy age-matched controls. However, compared to controls,
patients did not develop an effective decision-making strategy
and tended to change their deck preferences more frequently
despite intact executive functions (Gescheidt et al., 2012). In
addition, Poletti et al. (2010) recently showed similar IGT per-
formance in de novo PD patients and healthy age-matched con-
trols, suggesting that decision-making deficits in early PD emerge
after dopaminergic medication rather than as a result of PD
per se.
In few studies, did the authors compare IGT performance of
PD patients with and without PG (Rossi et al., 2010; Bentivoglio
et al., 2012). Rossi et al. (2010) found that PD patients with PG per-
formed significantly worse on the IGT than PD patients without
PG, whereas Bentivoglio et al. (2012) noted only a trend toward
poorer performance characterized by more risky choices and
greater monetary loss in patients with impulse control disorders
compared to PD controls.
The decision-making impairments observed in PD patients
with and without PG are held widely to be related to deficits
in the fronto-striatal circuitry (Brand et al., 2004; Perretta et al.,
2005; Cools, 2006; Mimura et al., 2006; Pagonabarraga et al., 2007;
Kobayakawa et al., 2008; Rowe et al., 2008; Cools et al., 2009;
Euteneuer et al., 2009; Ibarretxe-Bilbao et al., 2009; Gleichgerrcht
et al., 2010; Poletti et al., 2010; Rossi et al., 2010). The involve-
ment of the ventral striatum, which appears especially important
in the underlying dopaminergic dysfunctions of PG, is uncertain
in medication-induced PG, particularly as related to dopamine
agonists, in PD (Perretta et al., 2005; Cools, 2006; Pagonabar-
raga et al., 2007; Rowe et al., 2008; Cools et al., 2009; Linnet
et al., 2010, 2011a; Peterson et al., 2010; Poletti et al., 2010).
While the dopaminergic mechanism of the increased risk of PG
in PD remains unknown, Steeves et al. (2009) find support for the
involvement of the ventral striatum in PG in PD by demonstrating
that PD patients with PG release significantly more dopamine in
the ventral striatum during gambling compared to PD patients
without PG.
This study was designed to compare dopaminergic neurotrans-
mission during gambling in 40- to 65-year-old male PD patients
with PG compared to PD patients without PG, pathological gam-
blers without PD, and healthy controls matched on age and gender.
Using [11C]raclopride positron emission tomography (PET), we
assessed changes in dopamine occupancy between a baseline and
an active gambling condition testing the hypothesis of increased
dopamine release in the ventral striatum upon gambling by PD
patients with PG and by pathological gamblers. Due to difficult
recruiting of subjects, particularly PD patients with PG, the study
was designed to allow for a continuous data collection without
methodological modifications prohibiting replication. Here we
present data from the first PD patient with PG and discuss
the results with reference to the results from four PD controls
without PG.
METHODS AND MATERIALS
SUBJECTS
The participant with PG was a 56-year-old married man, GL, with
a 15-year history of PD recruited through the Danish Parkinson
Association. He had a history of recreational gambling, but his
gambling behavior had been pathological for the past 11 years. He
had no history of smoking or drug use. The four PD controls were
male patients aged 41–59 years (mean= 50 years) with a history
of PD of 5–7 years (mean= 6 years). They had no history of gam-
bling, nor smoking, or drug use. All subjects gave written informed
consent before entering the study, which was approved by the local
ethical committee and performed in accordance with the Helsinki
II declaration.
CLINICAL ASSESSMENT
Parkinson’s disease variables were evaluated using a demographic
and clinical questionnaire consisting of 24 items including motor
symptomatology (10 yes/no questions about tremor, ON/OFF
periods, postural instability, bradykinesia, rigidity, dyskinesia,
freezing, problems swallowing, and muscle pain or numbness)
and medication. We evaluated the patients’ gambling behavior the
South Oaks Gambling Screen (SOGS) (Lesieur and Blume, 1987)
and the Structured Clinical Interview for DSM-IV Axis I disorders
(SCID-I) (First et al., 2002), which also screened for additional
Axis I psychopathology including mood and anxiety disorders and
substance use disorders. The SOGS is a self-administered ques-
tionnaire ranging from 0 to 20, assessing presence and severity
of gambling symptoms. A score of 5 or more indicates probable
PG (Lesieur and Blume, 1987). The SOGS has shown good reli-
ability and validity with the DSM-IV criteria for PG (Stinchfield,
2002). Furthermore, we screened for depressive symptomatology
using the 15-item Geriatric Depression Scale (GDS) (Sheikh and
Yesavage, 1986; Burke et al., 1991; Djernes et al., 2004). The GDS
is a 15-item forced-choice questionnaire estimating severity in
symptoms of depression in elderly that has been validated for
both younger and older patients with PD (Weintraub et al., 2006a,
2007). A score of 5 or above indicates probable depression with a
higher score indicating increased severity in symptoms. Finally,
the subjects answered the Zuckerman Sensation Seeking Scale
(Zuckerman, 1994), which is a 40-item forced-choice question-
naire assessing the personality trait sensation seeking characterized
by disinhibition, thrill and adventure seeking, experience seeking,
and boredom susceptibility (Zuckerman, 1994). Within the gen-
eral population, the Sensation Seeking Score is normally distrib-
uted around 20 with a standard deviation around 5 (Zuckerman,
1994).
IGT PARADIGM
The IGT is a card game consisting of four decks of cards labeled
A, B, C, and D in the first round, K, L, M, and N in the second
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round, and Q, R, S, and T in the third round. In each round, two
decks are advantageous decks leading to an overall gain, whereas
two decks are disadvantageous leading to an overall loss. For the
purpose of the current study, we focused on performance in the
ABCD round, in which decks A and B are disadvantageous decks
characterized by large immediate rewards and at unpredictable
time points even higher punishments leading to a net loss. In
contrast, decks C and D are advantageous decks associated with
smaller immediate rewards and even smaller delayed losses result-
ing in a net gain over time. Besides the monetary outcome the
IGT provides a measure of performance, an IGT score, which is
calculated by subtracting the number of disadvantageous selec-
tions from advantageous selections [(C+D)–(A+B)] (Denburg
et al., 2006). Here, we used a computerized version of the IGT opti-
mized for use with PET, which was presented for the subjects in
the scanner via an overhead monitor. The participants made 100
selections in each round using a right-handed computer mouse,
and each selection was followed by varying monetary gains and/or
losses as described above.
EXPERIMENTAL PROCEDURE
The subjects underwent two PET scans with a Siemens HRRT PET
scanner in 3D acquisition mode during both of which dynamic
emission recordings were obtained in 23 frames of increasing
duration for 60 min following an i.v. bolus injection of the radioli-
gand [11C]raclopride (mean: 312.6 MBq, range: 225–340 MBq).
For each condition, a brief attenuation scan was obtained just
prior to the dynamic scan. In the first 60-min baseline condition
the computer automatically informed the subject which card to
pick from the decks. In the second 60-min active gambling condi-
tion the participant had to make his own decisions throughout
the 100 selections. Following PET scanning, we obtained T1-
weighted anatomical 1.2 Miami 3D magnetic resonance (MR)
images in a 3.0 T GE MR scanner to enable co-registration with
PET images.
IMAGE ANALYSIS
Emission recordings summed over the whole hour of PET scan-
ning for both conditions were individually registered to the native
MR images using the Montreal Neurological Institute (MNI) tool-
box (Collins et al., 1994). Subsequently, the MR/PET correlated
images were transformed into a common stereotaxic coordinate
space (Talairach and Tournoux, 1988), and anatomical volumes
of interest were used to extract time-activity-curves (TACs) from
the dynamic PET images for each subject and each scan. Using
cerebellar TACs as reference, we obtained voxel-wise maps of
[11C]raclopride binding potentials (BP) for both the baseline
(BPbaseline) and the active gambling condition (BPgambling). From
these maps we extracted the average BP value for each region of
interest, putamen, caudate nucleus, and ventral striatum, left and
right hemisphere separately, using the Simplified Reference Tissue
Model (SRTM) (Lammertsma and Hume, 1996). The BP of a given
radioligand, in this case [11C]raclopride, is an estimate of receptor
availability, i.e., an index of the number of receptors available for
binding (Gjedde et al., 2005).
We calculated changes in raclopride binding potentials (∆BP)
for each region of interest, for both sessions. The change
in binding potential upon gambling normalized to the base-
line binding potential was calculated as: ∆BP= (BPgambling–
BPbaseline)/BPbaseline. Thus, a gambling-evoked decrease of
[11C]raclopride binding indicates an increase in dopamine occu-
pancy, associated with an increase in the extracellular dopamine
concentration, a decreased affinity of the receptors toward
dopamine, a decreased number of receptors, or two or all of
the above combined. Conversely, an IGT-induced increase in BP
reflects a decline in dopamine occupancy.
RESULTS
CLINICAL ASSESSMENT
At the time of participation, GL received 300 mg/day of levodopa
controlled release, 8 mg/day of cabergoline, and 600 mg/day of
entacapone, converted into a total levodopa equivalent daily dose
(LEDD) of 857.6 mg/day using the standard conversion factors
described by Tomlinson et al. (2010). After 3 years, we had the
chance to examine GL again. At that time he no longer received
levodopa and only 1 mg/day rasagiline and 4 mg/day ropinirole
equal to a total LEDD of 180 mg/day. However, his gambling prob-
lem was persistent. PD controls received levodopa, pramipexole,
ropinirole, rotigotin, and rasagiline equivalent to a mean total
LEDD of 797.4 mg/day. The results of the clinical evaluation are
summarized in Table 1.
IGT PERFORMANCE
We calculated the overall IGT score and evaluated GL’s IGT per-
formance across 100 selections. He predominantly picked cards
from deck D leading to an overall positive result, but displayed a
preference for deck B as well. Of 100 choices he picked 13 cards
from deck A, 30 cards from deck B, 20 cards from deck C, and
37 cards from deck D, resulting in an IGT score of 14. Overall,
PD controls showed a preference for deck D, though they tended
to pick cards from decks B, C, and D equally often leading to a
positive mean IGT score of 17.5 (range:−8 to 62). On average, PD
controls picked 15 cards from deck A (range: 4–29), 27 from deck
B (range: 13–48), 23 from deck C (range: 1–46), and 35 from deck
D (range: 25–47).
PET IMAGING
For all subjects, we obtained parametric voxel-wise maps of
[11C]raclopride BP for both the baseline and the IGT condition as
illustrated in Figure 1.
From the parametric maps we extracted the average BP for each
region of interest, putamen, caudate nucleus, and ventral striatum,
left and right hemisphere, for both sessions and calculated changes
in [11C]raclopride binding for each region of interest. The BPs are
summarized in Tables 2 and 3.
DISCUSSION
The purpose of the current case study was to investigate dopamin-
ergic neurotransmission during IGT performance in PD patients
with PG and to explore clinical correlates of PG in PD. When
we first evaluated GL, his regimen included a high dose of
dopaminergic medication, particularly dopamine agonists, and
he displayed many symptoms of PG. Despite a change in med-
ication and a marked reduction of the total dose, he reported
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Table 1 | Clinical assessment of medication, depressive
symptomatology, gambling severity, and sensation seeking.
GL
day 1
GL
follow-up
PD controls
mean (range)
Total LEDD (mg/day) 857.6 180 797.4 (360–1114.5)
DA LEDD (mg/day) 533.6 80 196.3 (60–315)
Motor symptoms (0–10) 6 10 4 (2–6)
SOGS 17 – 0
Current PG Yes Yes No
GDS 3 3 1 (0–3)
Sensation seeking score 27 – 17 (11–23)
Pu, putamen; Cn, caudate nucleus; Vst, ventral striatum; BP, binding potential;
∆BP, change in binding potential.
FIGURE 1 | Illustrates a decrease in striatal [11C]raclopride binding from
baseline (A) to IGT performance (B).
persistent gambling behavior after 3 years, still spending 4 h a
day on casinos, internet gambling, lotteries, scratch cards, odds,
slot machines, and horse betting. Previous studies indicate that
reducing the amount of dopaminergic medication, particularly
dopamine agonist dose, often relieves or reduces PG symptoms
(Molina et al., 2000; Dodd et al., 2005; Avanzi et al., 2006; Wein-
traub et al., 2006b; Weintraub and Nirenberg, 2012). In this case,
gambling behavior remained, though symptoms improved follow-
ing treatment changes. Unfortunately, GL displayed more motor
symptoms at follow-up, probably as a consequence of disease pro-
gression but possibly also related to the dramatic reduction of
Table 2 | [11C]raclopride binding potentials for the putamen, caudate
nucleus, and ventral striatum, left and right hemisphere in GL.
BP, baseline
mean (SD)
BP, gambling
mean (SD)
∆BP ∆BP in%
Pu, left 2.50 (0.96) 2.26 (0.78) −0.24 −9.42
Pu, right 2.40 (0.82) 2.16 (0.71) −0.24 −9.95
Cn, left 1.37 (0.73) 1.26 (0.67) −0.11 −8.00
Cn, right 1.30 (0.71) 1.30 (0.70) 0.00 0.00
Vst, left 1.78 (0.63) 1.36 (0.54) −0.44 −24.92
Vst, right 1.39 (0.55) 1.28 (0.49) −0.12 −8.32
LEDD, levodopa equivalent daily dose; DA, dopamine agonist; SOGS, South Oaks
Gambling Screen; PG, pathological gambling; GDS, geriatric depression scale; SD,
standard deviation.
Table 3 | Mean [11C]raclopride binding potentials for the putamen,
caudate nucleus, and ventral striatum, left and right hemisphere in
four PD patients without PG.
BP, baseline
mean (SD)
BP, gambling
mean (SD)
∆BP
mean (SD)
∆BP in %
mean (SD)
Pu, left 2.95 (1.12) 2.93 (1.39) −0.03 (0.40) −2.88 (0.12)
Pu, right 2.72 (0.88) 2.61 (1.19) −0.11 (0.37) −6.64 (0.12)
Cn, left 1.84 (0.70) 1.80 (0.88) −0.04 (0.19) −4.60 (0.10)
Cn, right 1.83 (0.71) 1.81 (0.94) −0.02 (0.28) −3.84 (0.13)
Vst, left 1.97 (0.72) 2.14 (1.02) 0.16 (0.37) 5.76 (0.15)
Vst, right 1.45 (0.36) 1.36 (0.47) −0.08 (0.22) −7.01 (0.17)
Pu, putamen; Cn, caudate nucleus; Vst, ventral striatum; BP, binding potential;
∆BP, change in binding potential; SD, standard deviation.
medication. Overall, at baseline GL did not differ from PD con-
trols in GDS score, but he displayed more motor symptoms, was
more sensation seeking, and received a higher dose of dopamine
agonists.
The primary finding of the study was the marked reduction
in [11C]raclopride binding during gambling, relative to baseline
binding, in the left ventral striatum observed in GL, suggesting
a gambling-induced dopamine release. In contrast, we noted no
gambling-evoked changes in BPs in PD controls, who instead
displayed a small increase of [11C]raclopride binding in the left
ventral striatum upon gambling. Similar physiological reactions
to gambling have been presented in both pathological gamblers
without PD (Linnet et al., 2010, 2011a; Peterson et al., 2010) and
in PD patients with PG (Steeves et al., 2009) releasing signifi-
cantly more dopamine in the ventral striatum during gambling
than PD patients without PG. However, the findings by Steeves
et al. (2009), indicated a bilateral dopamine release in the ventral
striatum in PD patients with PG, but unilateral in the left ventral
striatum in PD patients without PG. Unfortunately, due to the
small number of subjects in this study so far, the issue of later-
alization remains unresolved, yet our preliminary results support
the hypothesis that this specific structure is implicated in PG and
addiction. The ventral striatum is essential to reinforcement of
behavior, and gambling-induced dopamine release in the ventral
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striatum might explain why pathological gamblers and PD patients
with PG continue gambling despite personal, social, and financial
consequences. In addition, compared to PD controls, GL displayed
lower striatal baseline BP, which also previously was associated
with an increased vulnerability to addiction and impulse control
disorders (Volkow et al., 2001, 2002; Wang et al., 2001; Nader et al.,
2006).
Considering GL’s decision-making strategy while performing
the IGT, we noted that, despite an overall positive IGT score and
a preference for deck D, he had a preference for the disadvan-
tageous deck B. He could not completely inhibit the impulse to
take the risk of a larger reward, despite the risk of an even larger
punishment. A similar preference for deck B has been found in
patients with early-onset PD (Gescheidt et al., 2012) who per-
formed almost as well as healthy controls on the IGT but failed
to develop an effective strategy. Instead their gambling behavior
was characterized by more frequent changes in deck preferences
resembling the gambling behavior we observed in both GL and
PD controls. A gambling strategy characterized by cards picked
almost equally often from advantageous and disadvantageous pre-
viously has been shown to elicit a larger dopamine release in
the ventral striatum in pathological gamblers, relative to very
poor or very good IGT performance (Linnet et al., 2012), consis-
tent with the IGT-induced dopamine release we observed in GL.
Interestingly, the dopaminergic response to gambling was absent
from PD controls, despite an almost identical gambling strat-
egy. Another possible explanation for the different ventral striatal
activity between the GL and PD controls is that the dopamin-
ergic response to gambling might be driven by the reward rate
attained during task performance, which differs depending on
the subjects’ decisions, rather than by the gambling aspect of
the task per se. However, as already mentioned the groups dis-
played almost similar decision-making behavior, diminishing the
difference in reward rates. Additionally, in contrast to the study
by Steeves et al. (2009), all participants in this study experi-
enced both rewards and penalties both at baseline and during
active gambling, ensuring that only the decision-making aspect
differed between conditions, thus supporting the argument of
a gambling-related dopamine release. Moreover, subjects always
ended up winning in the study by Steeves et al. (2009), which
despite enhanced stimuli control might reduce the ecological
validity of the gambling task and thus diminish the element of
risky decision-making. This might explain the relatively smaller
gambling-related dopamine release in PD patients with PG pre-
sented by Steeves et al. (2009) relative to a somewhat larger reduc-
tion in [11C]raclopride binding observed in GL. Nevertheless, in
order to determine whether the different dopaminergic response
between groups is determined by the actual reward rate attained,
the expectation of reward, the level of excitement, or by the gam-
bling aspect itself more participants need to be included in the
study.
In addition, GL’s tendency to prefer immediate rewards and
devalue delayed rewards, referred to as temporal or delayed dis-
counting, likewise has been found in previous studies of impulse
control disorders in PD (Housden et al., 2010; Voon et al., 2010,
2011a,b), linking the disinhibited behavior to dopaminergic med-
ication, particularly the dopamine agonists (Housden et al., 2010;
Voon et al., 2010, 2011b; Voon and Dalley, 2011), as the tendency
toward risky decision-making may result from the high dose of
dopamine agonists. While the total LEDD was not very differ-
ent between GL and PD controls, GL was prescribed a very high
dopamine agonist LEDD compared to PD controls. Dopamine
agonists previously were associated with increased novelty seeking
(Bodi et al., 2009), and hence another possible explanation, which
adds on the findings by Steeves et al. (2009) discussed above, is
the relatively high level of sensation seeking characterizing GL.
His sensation seeking score of 27 is more than a standard devia-
tion above the mean in the general population, and very unlike the
general PD population, which is less sensation and novelty seeking
than healthy controls (Poletti and Bonuccelli, 2012). However, the
average sensation seeking score in PD controls resembled that in
the general population, though with a large variance. While two
PD controls did in fact reveal a low sensation seeking level of 11
and 12, respectively, the remaining two displayed scores very close
to the general population of 20 and 23, respectively.
Some limitations must be considered. First, presenting data
from a single case does not allow for statistical analyses to be made
and general conclusions to be drawn. Nevertheless, the findings
are in line with prior findings linking high doses of dopaminergic
medication to impaired decision-making and PG in PD as well
as implicating the ventral striatum in PG. Secondly, the clinical
assessment at follow-up did not include the entire battery of mea-
surements used on day 1, which compromises direct comparisons
and limits the conclusions which can be drawn from the study. We
were unable to determine whether the level of sensation seeking
would have changed with reduction of the medication dose, or
whether GL on a lower medication dose would have performed
better on the IGT, e.g., by less preference for deck B. Finally, the
IGT is not the game of choice for GL and may have resulted in a
slightly lower dopamine release following gambling. On the other
hand, the expectation of reward is essential in inducing striatal
dopamine release in pathological gamblers.
In conclusion, the findings suggest that PG in PD is associ-
ated with high doses of a dopamine agonist, long PD duration,
pronounced motor symptomatology, a high level of sensation
seeking, and risky decision-making associated with an altered
dopamine response that reinforces gambling behavior. Thus, the
marked decrease in ventral striatal [11C]raclopride binding during
gambling, observed in GL, implies a gambling-induced dopamine
release not seen in PD controls, which may explain how PD
patients with PG continue gambling despite personal, social, and
financial consequences. Overall, the findings support the concept
of dopamine agonist related PG in PD and underline the impor-
tance of taking clinical variables, such as age, disease duration, and
personality, into account when medicating patients with PD, to
reduce the risk of PG.
ACKNOWLEDGMENTS
We thank the Danish Agency for Science, Technology, and
Innovation for financial support, grant number 2102-07-0005.
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2013 | Volume 7 | Article 95 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Callesen et al. Dopamine and gambling in Parkinson’s disease
REFERENCES
APA. (1994). APA. Diagnostic and Sta-
tistical Manual of Mental Disorders,
Fourth Revision (DSM-IV). Wash-
ington, DC: American Psychiatric
Association.
Avanzi,M.,Baratti,M.,Cabrini,S.,Uber,
E.,Brighetti,G.,and Bonfa,F. (2006).
Prevalence of pathological gambling
in patients with Parkinson’s disease.
Mov. Disord. 21, 2068–2072. doi:10.
1002/mds.21072
Bechara, A., Damasio, A. R., Dama-
sio, H., and Anderson, S. W.
(1994). Insensitivity to future con-
sequences following damage to
human prefrontal cortex. Cogni-
tion 50, 7–15. doi:10.1016/0010-
0277(94)90018-3 [Research Sup-
port, Non-U.S. Gov’t Research Sup-
port, U.S. Gov’t, P.H.S.].
Bentivoglio, A. R., Baldonero, E., Ric-
ciardi, L., De Nigris, F., and Daniele,
A. (2012). Neuropsychological fea-
tures of patients with Parkinson’s
disease and impulse control dis-
orders. Neurol. Sci. doi:10.1007/
s10072-012-1224-5. [Epub ahead of
print].
Bodi, N., Keri, S., Nagy, H., Moustafa,A.,
Myers, C. E., Daw, N., et al. (2009).
Reward-learning and the novelty-
seeking personality: a between- and
within-subjects study of the effects
of dopamine agonists on young
Parkinson’s patients. Brain 132(Pt
9), 2385–2395. doi:10.1093/brain/
awp094 [Research Support, N.I.H.,
Extramural Research Support, Non-
U.S. Gov’t].
Brand, M., Labudda, K., Kalbe, E.,
Hilker, R., Emmans, D., Fuchs, G., et
al. (2004). Decision-making impair-
ments in patients with Parkinson’s
disease. Behav. Neurol. 15, 77–85.
Burke, W. J., Roccaforte, W. H., and
Wengel, S. P. (1991). The short
form of the Geriatric Depression
Scale: a comparison with the 30-
item form. J. Geriatr. Psychiatry
Neurol. 4, 173–178. doi:10.1177/
089198879100400310 [Comparative
Study].
Callesen, M. B., Scheel-Krüger, J.,
Kringelbach, M. L., and Møller, A. A.
(2013). Systematic review of impulse
control disorders in Parkinson’s dis-
ease. J. Parkinsons Dis. 3, 105–138.
Claassen, D. O., van den Wildenberg,
W. P., Ridderinkhof, K. R., Jessup, C.
K., Harrison, M. B., Wooten, G. F.,
et al. (2011). The risky business of
dopamine agonists in Parkinson dis-
ease and impulse control disorders.
Behav. Neurosci. 125, 492–500. doi:
10.1037/a0023795 [Research Sup-
port, N.I.H., Extramural Research
Support, Non-U.S. Gov’t].
Collins, D. L., Neelin, P., Peters, T. M.,
and Evans, A. C. (1994). Automatic
3D intersubject registration of
MR volumetric data in standard-
ized Talairach space. J. Comput.
Assist. Tomogr. 18, 192–205. doi:10.
1097/00004728-199403000-00005
[Research Support, Non-U.S.
Gov’t].
Cools, R. (2006). Dopaminergic
modulation of cognitive function-
implications for L-DOPA treatment
in Parkinson’s disease. Neurosci.
Biobehav. Rev. 30, 1–23. doi:10.
1016/j.neubiorev.2005.03.024
Cools, R., Frank, M. J., Gibbs, S.
E., Miyakawa, A., Jagust, W., and
D’Esposito, M. (2009). Striatal
dopamine predicts outcome-specific
reversal learning and its sensitivity to
dopaminergic drug administration.
J. Neurosci. 29, 1538–1543. doi:10.
1523/JNEUROSCI.4467-08.2009
Denburg, N. L., Recknor, E. C.,
Bechara, A., and Tranel, D. (2006).
Psychophysiological anticipation of
positive outcomes promotes advan-
tageous decision-making in nor-
mal older persons. Int. J. Psy-
chophysiol. 61, 19–25. doi:10.1016/j.
ijpsycho.2005.10.021 [Research Sup-
port, N.I.H., Extramural].
Djernes, J. K., Kvist, E., Olesen, F.,
Munk-Jorgensen, P., and Gulmann,
N. C. (2004). [Validation of a Dan-
ish translation of Geriatric Depres-
sion Scale-15 as a screening tool
for depression among frail elderly
living at home]. Ugeskr. Laeg. 166,
905–909. [Validation Studies].
Dodd, M. L., Klos, K. J., Bower, J.
H., Geda, Y. E., Josephs, K. A.,
and Ahlskog, J. E. (2005). Patho-
logical gambling caused by drugs
used to treat Parkinson disease.Arch.
Neurol. 62, 1377–1381. doi:10.1001/
archneur.62.9.noc50009
Euteneuer, F., Schaefer, F., Stuermer,
R., Boucsein, W., Timmermann, L.,
Barbe, M. T., et al. (2009). Disso-
ciation of decision-making under
ambiguity and decision-making
under risk in patients with Parkin-
son’s disease: a neuropsychological
and psychophysiological study.
Neuropsychologia 47, 2882–2890.
doi:10.1016/j.neuropsychologia.
2009.06.014 [Controlled Clinical
Trial Research Support, Non-U.S.
Gov’t].
First, M. B., Spitzer, R., Gibbon, M., and
Williams, J. (2002). Structured Clin-
ical Interview for DSM-IV-Tr Axis
I Disorders, Research Version, Non-
Patient Edition (SCID-I/Np). New
York: Biometrics Research.
Frank, M. J., Samanta, J., Moustafa,
A. A., and Sherman, S. J. (2007).
Hold your horses: impulsiv-
ity, deep brain stimulation,
and medication in parkinson-
ism. Science 23, 1309–1312.
doi:10.1126/science.1146157
Gescheidt, T., Czekoova, K., Urbanek,
T., Marecek, R., Mikl, M., Kubikova,
R., et al. (2012). Iowa Gambling
Task in patients with early-onset
Parkinson’s disease: strategy analy-
sis. Neurol. Sci. 33, 1329–1335.
doi:10.1007/s10072-012-1086-x
[Research Support, Non-U.S.
Gov’t].
Gjedde, A., Wong, D. F., Rosa-Neto,
P., and Cumming, P. (2005). Map-
ping neuroreceptors at work: on
the definition and interpretation of
binding potentials after 20 years
of progress. Int. Rev. Neurobiol. 63,
1–20. doi:10.1016/S0074-7742(05)
63001-2 [Review].
Gleichgerrcht, E., Ibanez, A., Roca, M.,
Torralva, T., and Manes, F. (2010).
Decision-making cognition in neu-
rodegenerative diseases. Nat. Rev.
Neurol. 6, 611–623. doi:10.1038/
nrneurol.2010.148 [Research Sup-
port, Non-U.S. Gov’t Review].
Goudriaan, A. E., Oosterlaan, J., de
Beurs, E., and van den Brink,
W. (2005). Decision making in
pathological gambling: a compari-
son between pathological gamblers,
alcohol dependents, persons with
Tourette syndrome,and normal con-
trols. Brain Res. Cogn. Brain Res. 23,
137–151. doi:10.1016/j.cogbrainres.
2005.01.017 [Clinical Trial Compar-
ative Study Research Support, Non-
U.S. Gov’t].
Goudriaan, A. E., Oosterlaan, J., de
Beurs, E., and van den Brink,
W. (2006). Neurocognitive func-
tions in pathological gambling: a
comparison with alcohol depen-
dence, Tourette syndrome and
normal controls. Addiction 101,
534–547. doi:10.1111/j.1360-
0443.2006.01380.x [Comparative
Study Research Support, Non-U.S.
Gov’t].
Grant, S., Contoreggi, C., and London,
E. D. (2000). Drug abusers show
impaired performance in a labora-
tory test of decision making. Neu-
ropsychologia 38, 1180–1187. doi:10.
1016/S0028-3932(99)00158-X
Housden, C. R., O’Sullivan, S. S.,
Joyce, E. M., Lees, A. J., and
Roiser, J. P. (2010). Intact reward
learning but elevated delay dis-
counting in Parkinson’s disease
patients with impulsive-compulsive
spectrum behaviors. Neuropsy-
chopharmacology 35, 2155–2164.
doi:10.1038/npp.2010.84 [Compar-
ative Study].
Ibarretxe-Bilbao, N., Junque, C., Tolosa,
E., Marti, M. J., Valldeoriola, F.,
Bargallo, N., et al. (2009). Neu-
roanatomical correlates of impaired
decision-making and facial emo-
tion recognition in early Parkin-
son’s disease. Eur. J. Neurosci.
30, 1162–1171. doi:10.1111/j.1460-
9568.2009.06892.x [Research Sup-
port, Non-U.S. Gov’t].
Joutsa, J., Martikainen, K., Vahlberg, T.,
Voon, V., and Kaasinen, V. (2012).
Impulse control disorders and
depression in Finnish patients with
Parkinson’s disease. Parkinsonism
Relat. Disord. 18, 155–160. doi:
10.1016/j.parkreldis.2011.09.007
[Randomized Controlled Trial].
Kim, J., Kim, M., Kwon, D. Y., Seo,
W. K., Kim, J. H., Baik, J. S., et
al. (2013). Clinical characteristics
of impulse control and repetitive
behavior disorders in Parkinson’s
disease. J. Neurol. 260, 429–437. doi:
10.1007/s00415-012-6645-9
Kobayakawa, M., Koyama, S., Mimura,
M., and Kawamura, M. (2008). Deci-
sion making in Parkinson’s disease:
analysis of behavioral and physio-
logical patterns in the Iowa gambling
task. Mov. Disord. 23, 547–552. doi:
10.1002/mds.21865 [Research Sup-
port, Non-U.S. Gov’t].
Lammertsma, A. A., and Hume, S.
P. (1996). Simplified reference tis-
sue model for PET receptor stud-
ies. Neuroimage 4(3 Pt 1), 153–158.
doi:10.1006/nimg.1996.0066
Lee, J. Y., Jeon, B. S., Kim, H. J., and
Park, S. S. (2012). Genetic variant
of HTR2A associates with risk
of impulse control and repetitive
behaviors in Parkinson’s disease.
Parkinsonism Relat. Disord. 18,
76–78. doi:10.1016/j.parkreldis.
2011.08.009 [Research Support,
Non-U.S. Gov’t].
Lesieur, H. R., and Blume, S. B.
(1987). The South Oaks Gambling
Screen (SOGS): a new instrument
for the identification of pathologi-
cal gamblers. Am. J. Psychiatry 144,
1184–1188.
Linnet, J., Moller, A., Peterson, E.,
Gjedde, A., and Doudet, D. (2011a).
Dopamine release in ventral stria-
tum during Iowa Gambling Task
performance is associated with
increased excitement levels in patho-
logical gambling. Addiction 106,
383–390. doi:10.1111/j.1360-0443.
2010.03126.x [Research Support,
Non-U.S. Gov’t].
Linnet, J., Moller, A., Peterson,
E., Gjedde, A., and Doudet,
D. (2011b). Inverse association
between dopaminergic neurotrans-
mission and Iowa Gambling Task
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2013 | Volume 7 | Article 95 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Callesen et al. Dopamine and gambling in Parkinson’s disease
performance in pathological gam-
blers and healthy controls. Scand.
J. Psychol. 52, 28–34. doi:10.1111/j.
1467-9450.2010.00837.x [Research
Support, Non-U.S. Gov’t].
Linnet, J., Mouridsen, K., Peterson,
E., Moller, A., Doudet, D. J.,
and Gjedde, A. (2012). Striatal
dopamine release codes uncertainty
in pathological gambling. Psychia-
try Res. 204, 55–60. doi:10.1016/
j.pscychresns.2012.04.012 [Research
Support, Non-U.S. Gov’t].
Linnet, J., Peterson, E., Doudet, D.
J., Gjedde, A., and Moller, A.
(2010). Dopamine release in
ventral striatum of pathological
gamblers losing money. Acta Psy-
chiatr. Scand. 122, 326–333. doi:
10.1111/j.1600-0447.2010.01591.x
[Research Support, Non-U.S.
Gov’t].
Linnet, J., Rojskjaer, S., Nygaard, J.,
and Maher, B. A. (2006). Episodic
chasing in pathological gamblers
using the Iowa gambling task.
Scand. J. Psychol. 47, 43–49. doi:
10.1111/j.1467-9450.2006.00491.x
[Research Support, Non-U.S.
Gov’t].
Manes, F., Sahakian, B., Clark, L.,
Rogers, R., Antoun, N., Aitken,
M., et al. (2002). Decision-making
processes following damage to the
prefrontal cortex. Brain 125(Pt 3),
624–639. doi:10.1093/brain/awf049
[Research Support, Non-U.S.
Gov’t].
Mimura, M., Oeda, R., and Kawamura,
M. (2006). Impaired decision-
making in Parkinson’s disease.
Parkinsonism Relat. Disord. 12,
169–175. doi:10.1016/j.parkreldis.
2005.12.003 [Research Support,
Non-U.S. Gov’t].
Molina, J. A., Sainz-Artiga, M. J.,
Fraile, A., Jimenez-Jimenez, F.
J., Villanueva, C., Orti-Pareja,
M., et al. (2000). Pathologic
gambling in Parkinson’s dis-
ease: a behavioral manifesta-
tion of pharmacologic treat-
ment? Mov. Disord. 15, 869–872.
doi:10.1002/1531-8257(200009)15:
5<869::AID-MDS1016>3.0.CO;2-I
Nader, M. A., Morgan, D., Gage, H.
D., Nader, S. H., Calhoun, T. L.,
Buchheimer, N., et al. (2006). PET
imaging of dopamine D2 recep-
tors during chronic cocaine self-
administration in monkeys. Nat.
Neurosci. 9, 1050–1056. doi:10.1038/
nn1737 [Research Support, N.I.H.,
Extramural].
Pagonabarraga, J., Garcia-Sanchez,
C., Llebaria, G., Pascual-Sedano,
B., Gironell, A., and Kulisevsky,
J. (2007). Controlled study of
decision-making and cognitive
impairment in Parkinson’s dis-
ease. Mov. Disord. 22, 1430–1435.
doi:10.1002/mds.21457
Perretta, J. G., Pari, G., and Beninger, R.
J. (2005). Effects of Parkinson dis-
ease on two putative nondeclarative
learning tasks: probabilistic classifi-
cation and gambling. Cogn. Behav.
Neurol. 18, 185–192. doi:10.1097/01.
wnn.0000187939.81541.1d
Peterson, E., Moller, A., Doudet, D. J.,
Bailey, C. J., Hansen, K. V., Rodell,
A., et al. (2010). Pathological gam-
bling: relation of skin conductance
response to dopaminergic neuro-
transmission and sensation-seeking.
Eur. Neuropsychopharmacol. 20,
766–775. doi:10.1016/j.euroneuro.
2010.07.010 [Research Support,
Non-U.S. Gov’t].
Petry, N. M. (2001). Substance abuse,
pathological gambling, and impul-
siveness. Drug Alcohol Depend. 63,
29–38. doi:10.1016/S0376-8716(00)
00188-5
Poletti, M., and Bonuccelli, U. (2012).
Impulse control disorders in Parkin-
son’ disease: the role of person-
ality and cognitive status. J. Neu-
rol. 259, 2269–2277. doi:10.1007/
s00415-012-6506-6
Poletti, M., Cavedini, P., and Bonuc-
celli, U. (2011). Iowa gambling task
in Parkinson’s disease. J. Clin. Exp.
Neuropsychol. 33, 395–409. doi:10.
1080/13803395.2010.524150
Poletti, M., Frosini, D., Lucetti, C., Del
Dotto, P., Ceravolo, R., and Bonuc-
celli, U. (2010). Decision making in
de novo Parkinson’s disease. Mov.
Disord. 25, 1432–1436. doi:10.1002/
mds.23098 [Research Support, Non-
U.S. Gov’t].
Rossi, M., Gerschcovich, E. R., de
Achaval, D., Perez-Lloret, S., Cer-
quetti, D., Cammarota, A., et al.
(2010). Decision-making in Parkin-
son’s disease patients with and with-
out pathological gambling. Eur. J.
Neurol. 17, 97–102. doi:10.1111/j.
1468-1331.2009.02792.x
Rowe, J. B., Hughes, L., Ghosh, B. C.,
Eckstein, D., Williams-Gray, C. H.,
Fallon, S., et al. (2008). Parkin-
son’s disease and dopaminergic ther-
apy – differential effects on move-
ment, reward and cognition. Brain
131(Pt 8), 2094–2105. doi:10.1093/
brain/awn112
Schreiber, L., Odlaug, B. L., and Grant,
J. E. (2011). Impulse control dis-
orders: updated review of clinical
characteristics and pharmacological
management. Front. Psychiatry 2:1.
doi:10.3389/fpsyt.2011.00001
Sheikh, J. I., and Yesavage, J. A. (1986).
Geriatric Depression Scale (GDS):
recent evidence and development
of a shorter version. Clin. Gerontol.
5, 165–173. doi:10.3109/09638288.
2010.503835
Steeves, T. D., Miyasaki, J., Zurowski,
M., Lang, A. E., Pellecchia, G., Van
Eimeren, T., et al. (2009). Increased
striatal dopamine release in Parkin-
sonian patients with pathological
gambling: a [11C] raclopride PET
study. Brain 132(Pt 5), 1376–1385.
doi:10.1093/brain/awp054
Stinchfield, R. (2002). Reliability, valid-
ity, and classification accuracy of
the South Oaks Gambling Screen
(SOGS).Addict. Behav. 27, 1–19. doi:
10.1016/S0306-4603(00)00158-1
Talairach, J., and Tournoux, P. (1988).
Co-Planar Stereotaxic Atlas of the
Human Brain. New York: Thieme
Verlag.
Tomlinson, C. L., Stowe, R., Patel, S.,
Rick, C., Gray, R., and Clarke, C.
E. (2010). Systematic review of lev-
odopa dose equivalency reporting in
Parkinson’s disease. Mov. Disord. 25,
2649–2653. doi:10.1002/mds.23429
[Research Support, Non-U.S. Gov’t
Review].
van Holst, R. J., van den Brink, W.,
Veltman, D. J., and Goudriaan, A.
E. (2010). Why gamblers fail to
win: a review of cognitive and neu-
roimaging findings in pathological
gambling. Neurosci. Biobehav. Rev.
34, 87–107. doi:10.1016/j.neubiorev.
2009.07.007 [Review].
Volkow, N. D., Chang, L., Wang, G.
J., Fowler, J. S., Ding, Y. S., Sedler,
M., et al. (2001). Low level of
brain dopamine D2 receptors
in methamphetamine abusers:
association with metabolism in
the orbitofrontal cortex. Am.
J. Psychiatry 158, 2015–2021.
doi:10.1176/appi.ajp.158.12.2015
[Research Support, U.S. Gov’t,
Non-P.H.S. Research Support, U.S.
Gov’t, P.H.S.].
Volkow, N. D., Fowler, J. S., and
Wang, G. J. (2002). Role of
dopamine in drug reinforcement
and addiction in humans: results
from imaging studies. Behav. Phar-
macol. 13, 355–366. doi:10.1097/
00008877-200209000-00008 [Com-
ment Research Support, U.S. Gov’t,
Non-P.H.S. Research Support, U.S.
Gov’t, P.H.S. Review].
Voon, V., and Dalley, J. W. (2011).
Parkinson disease: impulsive choice-
Parkinson disease and dopamin-
ergic therapy. Nat. Rev. Neurol.
7, 541–542. doi:10.1038/nrneurol.
2011.139 [News].
Voon, V., Gao, J., Brezing, C.,
Symmonds, M., Ekanayake,
V., Fernandez, H., et al.
(2011a). Dopamine agonists
and risk: impulse control dis-
orders in Parkinson’s disease.
Brain 134(Pt 5), 1438–1446.
doi:10.1093/brain/awr080 [Clinical
Trial Research Support, N.I.H.,
Intramural].
Voon, V., Sohr, M., Lang, A. E., Potenza,
M. N., Siderowf, A. D., Whetteckey,
J., et al. (2011b). Impulse control dis-
orders in Parkinson disease: a multi-
center case–control study.Ann. Neu-
rol. 69, 986–996. doi:10.1002/ana.
22356 [Research Support, Non-U.S.
Gov’t].
Voon, V., Reynolds, B., Brezing, C.,
Gallea, C., Skaljic, M., Ekanayake, V.,
et al. (2010). Impulsive choice
and response in dopamine
agonist-related impulse con-
trol behaviors. Psychopharma-
cology (Berl.) 207, 645–659.
doi:10.1007/s00213-009-1697-y
[Research Support, N.I.H., Extra-
mural Research Support, Non-U.S.
Gov’t].
Voon, V., Thomsen, T., Miyasaki, J.
M., de Souza, M., Shafro, A., Fox,
S. H., et al. (2007). Factors asso-
ciated with dopaminergic drug-
related pathological gambling in
Parkinson disease. Arch. Neurol. 64,
212–216. doi:10.1001/archneur.64.
2.212
Wang, G. J., Volkow, N. D., Logan, J.,
Pappas, N. R., Wong, C. T., Zhu,
W., et al. (2001). Brain dopamine
and obesity. Lancet 357, 354–357.
doi:10.1016/S0140-6736(00)03643-
6 [Research Support, U.S. Gov’t,
Non-P.H.S. Research Support, U.S.
Gov’t, P.H.S.].
Weintraub, D., Koester, J., Potenza, M.
N., Siderowf, A. D., Stacy, M., Voon,
V., et al. (2010). Impulse control dis-
orders in Parkinson disease: a cross-
sectional study of 3090 patients.
Arch. Neurol. 67, 589–595. doi:10.
1001/archneurol.2010.65 [Research
Support, Non-U.S. Gov’t].
Weintraub, D., and Nirenberg, M. J.
(2012). Impulse control and related
disorders in Parkinson’s disease.
Neurodegener. Dis. 11, 63–71. doi:10.
1159/000341996
Weintraub, D., Oehlberg, K. A., Katz,
I. R., and Stern, M. B. (2006a).
Test characteristics of the 15-
item geriatric depression scale
and Hamilton depression rating
scale in Parkinson disease. Am. J.
Geriatr. Psychiatry 14, 169–175.
doi:10.1097/01.JGP.0000192488.
66049.4b [Research Support,
N.I.H., Extramural Validation
Studies].
Weintraub, D., Siderowf, A. D., Potenza,
M. N., Goveas, J., Morales, K. H.,
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2013 | Volume 7 | Article 95 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Callesen et al. Dopamine and gambling in Parkinson’s disease
Duda, J. E., et al. (2006b). Asso-
ciation of dopamine agonist use
with impulse control disorders in
Parkinson disease. Arch. Neurol.
63, 969–973. doi:10.1001/archneur.
63.7.969 [Research Support, N.I.H.,
Extramural Research Support, Non-
U.S. Gov’t].
Weintraub, D., Saboe, K., and Stern, M.
B. (2007). Effect of age on geriatric
depression scale performance in
Parkinson’s disease. Mov. Disord. 22,
1331–1335. doi:10.1002/mds.21369
[Research Support, N.I.H., Extra-
mural].
Wu, K., Politis, M., and Piccini,
P. (2009). Parkinson disease and
impulse control disorders: a review
of clinical features, pathophysiology
and management. Postgrad. Med.
J. 85, 590–596. doi:10.1136/pgmj.
2008.075820 [Review].
Zuckerman, M. (1994). Behavioral
Expressions and Biosocial Bases of
Sensation Seeking . New York: Cam-
bridge University Press.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 10 June 2013; accepted: 13 July
2013; published online: 29 July 2013.
Citation: Callesen MB, Hansen KV,
Gjedde A, Linnet J and Møller A
(2013) Dopaminergic and clinical cor-
relates of pathological gambling in
Parkinson’s disease: a case report.
Front. Behav. Neurosci. 7:95. doi:
10.3389/fnbeh.2013.00095
Copyright © 2013 Callesen, Hansen,
Gjedde, Linnet and Møller . This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion License, which permits use, distrib-
ution and reproduction in other forums,
provided the original authors and source
are credited and subject to any copyright
notices concerning any third-party graph-
ics etc.
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2013 | Volume 7 | Article 95 | 8
